{"url_path":"/sec/sngx/8-k/2026-06-26/item-8-01","section_key":"item-8-01","section_title":"Item 8.01 ****Other Events.**","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-26","source_url":"https://www.sec.gov/Archives/edgar/data/812796/0001104659-26-078251-index.html","accession_number":"0001104659-26-078251","cik":"0000812796","ticker":"SNGX","issuer_name":"SOLIGENIX, INC.","edgar_url":"https://www.sec.gov/Archives/edgar/data/812796/0001104659-26-078251-index.html","primary_entity_key":"0000812796","primary_entity_name":"SOLIGENIX, INC."},"word_count":136,"has_tables":true,"body_markdown":"**Item 8.01****Other Events.**\n\n \n\nOn June 26, 2026, Soligenix, Inc. (the “Company”) filed a prospectus supplement (the “Current Prospectus Supplement”) to increase the maximum aggregate offering amount of the shares of the Company’s common stock, par value $0.001 per share, issuable under the At Market Issuance Sales Agreement, dated January 23, 2026 (the “Sales Agreement”), with Rodman & Renshaw LLC, by an additional aggregate amount of $2,500,000. The Company previously sold approximately $6,234,000 of shares of common stock pursuant to the Sales Agreement under prior prospectus supplements covering an aggregate of up to $6,406,000 of shares of common stock. A copy of the legal opinion as to the legality of the $2,500,000 of shares of common stock issuable under the Sales Agreement and covered by the Current Prospectus Supplement is filed as Exhibit 5.1 attached hereto.\n\n​"}